NCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
Clinical Trials
6 trialsNCT04439266 2025-11-19
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06357975 2025-10-31
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04439253 2025-09-18
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02419287 2023-03-06
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
University of Milano Bicocca
Phase 2 Completed